

Rec'd PCT/PTO 24 JUL 2001

FORM PTO-1390		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTORNEY'S DOCKET NUMBER 55859-019
TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A FILING UNDER 35 U.S.C. 371			U.S. APPLIC. NO. (if known, see 37 CFR 1.5) 09/889883
INTERNATIONAL APPLICATION NO. PCT/US00/32316	INTERNATIONAL FILING DATE November 24, 2000	PRIORITY DATE CLAIMED November 24, 1999	
TITLE OF INVENTION IMPROVED INOCULANT STRAINS OF BRADYRHIZOBIUM JAPONICUM			
APPLICANT(S) FOR DO/EO/US Arvind A. BHAGWAT and Donald KEISTER			
Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:			
1.	<input checked="" type="checkbox"/>	This is a FIRST submission of items concerning a filing under 35 U.S.C. 371.	
2.	<input type="checkbox"/>	This is a SECOND or SUBSEQUENT submission of items concerning a filing under 35 U.S.C. 371.	
3.	<input checked="" type="checkbox"/>	This express request to begin national examination procedures (35 U.S.C. 371(f)) at any time rather than delay examination until the expiration of the applicable time limit set in 35 U.S.C. 371(b) and PCT Articles 22 and 39(1).	
4.	<input type="checkbox"/>	A proper Demand for International Preliminary Examination was made by the 19th month from the earliest claimed priority date.	
5.	<input checked="" type="checkbox"/>	A copy of the International Application as filed (35 U.S.C. 371(c)(2))	
6.		a. <input type="checkbox"/> is transmitted herewith (required only if not transmitted by the International Bureau).	
7.		b. <input checked="" type="checkbox"/> has been transmitted by the International Bureau.	
8.		c. <input type="checkbox"/> is not required, as the application was filed in the United States Receiving Office (RO/US)	
9.	<input checked="" type="checkbox"/>	A translation of the International Application into English (35 U.S.C. 371(c)(2)).	
10.	<input type="checkbox"/>	Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3))	
		a. <input type="checkbox"/> are transmitted herewith (required only if not transmitted by the International Bureau).	
		b. <input type="checkbox"/> have been transmitted by the International Bureau.	
		c. <input type="checkbox"/> have not been made; however, the time limit for making such amendment has NOT expired.	
		d. <input type="checkbox"/> have not been made and will not be made.	
	<input type="checkbox"/>	A translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).	
	<input type="checkbox"/>	An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)).	
10.	<input type="checkbox"/>	A translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)).	
Items 11. to 16. below concern other document(s) or information included:			
11.	<input checked="" type="checkbox"/>	An Information Disclosure Statement under 37 CFR 1.97 and 1.98.	
12.	<input type="checkbox"/>	An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.	
13.	<input type="checkbox"/>	A FIRST preliminary amendment.	
	<input type="checkbox"/>	A SECOND or SUBSEQUENT preliminary amendment.	
14.	<input type="checkbox"/>	A substitute specification.	
15.	<input type="checkbox"/>	A change of power of attorney and/or address letter.	
16.	<input checked="" type="checkbox"/>	Other items or information.	
		1. International Search Report prepared by ISA/US	
		2. Formal Drawings	



20277

PATENT TRADEMARK OFFICE

JC17 Rec'd PCT/PTO 24 JUL 2001

U.S. APPLIC. NO. (if known, see 37 CFR 1.50) 09/889883		INTERNATIONAL APPLICATION NO. PCT/US00/32316		ATTORNEY'S DOCKET NUMBER 55859-016	
				CALCULATIONS	PTO USE ONLY
17. <input checked="" type="checkbox"/> The following fees are submitted: Basic National Fee (37 CFR 1.492(a)(1)-(5)): Search Report has been prepared by the EPO or JPO \$860.00 International preliminary examination fee paid to USPTO (37 CFR 1.482) \$690.00 No international preliminary examination fee paid to USPTO (37 CFR 1.482) but international search fee paid to USPTO (37 CFR 1.445(a)(2)) \$710.00 Neither international preliminary examination fee (37 CFR 1.482) nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO \$1,000.00 International preliminary examination fee paid to USPTO (37 CFR 1.482) and all claims satisfied provisions of PCT Article 33(2)-(4) \$100.00 <div style="text-align: right;">ENTER APPROPRIATE BASIC FEE AMOUNT =</div>					
Surcharge of \$130.00 for furnishing the oath or declaration later than <input checked="" type="checkbox"/> 20 <input type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492(e)).				\$ 130.00	
Claims	Number Filed	Number Extra	Rate		
Total Claims	15 -20 =		x \$18.00	\$	
Independent Claims	4 -3 =	1	x \$80.00	\$ 80.00	
Multiple dependent claim(s) (if applicable)			+ \$270.00	\$	
TOTAL OF ABOVE CALCULATIONS =				\$ 920.00	
Reduction by 1/2 for filing by small entity, if applicable. Verified Small Entity Statement must also be filed. (Note 37 CFR 1.9, 1.27, 1.28).				\$	
SUBTOTAL =				\$ 920.00	
Processing fee of \$130.00 for furnishing the English translation later than the <input type="checkbox"/> 20 <input type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492(f)).				\$	
TOTAL NATIONAL FEE =				\$ 920.00	
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40.00 per property				\$	
TOTAL FEES ENCLOSED =				\$ 920.00	
				Amount to be: refunded	\$
				charged	\$
a. <input type="checkbox"/> A check in the amount of \$ _____ to cover the above fees is enclosed. b. <input checked="" type="checkbox"/> Please charge my Deposit Account No. <u>500417</u> in the amount of \$ <u>920.00</u> to cover the above fees. A duplicate copy of this sheet is enclosed. c. <input checked="" type="checkbox"/> The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. <u>500417</u> . A duplicate copy of this sheet is enclosed.					
NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.					
SEND ALL CORRESPONDENCE TO:					
McDERMOTT, WILL & EMERY 600 13 th Street, N.W. Washington, DC 20005-3096 (202) 756-8000 Facsimile (202) 756-8087					
SIGNATURE <i>Robert L. Price</i> Robert L. Price NAME 22,685 REGISTRATION NUMBER July 24, 2001 DATE					

Docket No.: 55859-019

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of :
Arvind A. BHAGWAT, et al. :
Serial No.: : Group Art Unit:
Filed: July 24, 2001 : Examiner:
For: IMPROVED INOCULANT STRAINS OF BRADYRHIZOBIUM JAPONICUM

TRANSMITTAL OF FORMAL DRAWINGS

Commissioner for Patents
Washington, DC 20231

Sir:

At the time the above application was filed, informal drawings were presented with the application.

The formal drawings are submitted herewith.

Respectfully submitted,

MCDERMOTT, WILL & EMERY

Robert L. Price

Robert L. Price
Registration No. 22,685

600 13th Street, N.W.
Washington, DC 20005-3096
(202) 756-8000 RLP:prp
Date: July 24, 2001
Facsimile: (202) 756-8087

Fig. 1. Competitive nodulation against Serogroup 123 strain



Fig. 2. Competitive nodulation phenotype of major *B. japonicum* serogroup strains against BJ 5019 (at the ratio of 100:1)

Fig. 3. Competitive nodulation on other legume hosts




FIGURE 4

CCATCGTACGAAACCTCACTCCACGCGTACCAGCGCACCAGCCGCGGCGCGGCCAGTCGGC
ACGACGGATTGATCAGCCAACGTCCGGGCGAGGTCCGCGCGAACGCGATGCGCTGGGTCTG
GCCGGAATCGATCGCGAGCGTGTGAGCCAATAGGGCTTCCAGCCGTCGTGAGCTTGTG (SEQ ID NO: 1)
[Tn5 insertin element 5]
AGCTTGTCGAGCAGGCGGAAGGGATGGCCGTGCAGGTGGAACACGGCGGTGAGGGGCGCGGG
GTTCTTGAGGGTCAGCACGACGGTGCGGCGGTCTCTGGTGCGGAAGGCCGGCGCCGACGAGG
TGGAGAAATCCGCAGGCCGCGTCCAACCGGTATCGGGTGACCGAGCGCGACATCGAACCGC
AGGGCGCCTTTGAGATCGAGCTGGTCGGGCAGGGCATTGCGAGGGAGCGGTTGTGGCGGCAA
CAGCGGCGCGCGCGCTCCAGTCTGCCGAGATCGAGAGGTTTCCGATCGGGCGGGCCTCCTT
GCCGTCATGCAGCAGAAATTGGGCCGATGTGGCTGCGTCCACAAAGCGTCGGGCCGTC (SEQ ID NO: 2)

3/ppts

IMPROVED INOCULANT STRAINS OF *BRADYRHIZOBIUM JAPONICUM*

BACKGROUND OF THE INVENTION

Extensive testing of *B. japonicum* strains isolated from nodules of soybean plants has led to the selection of strains best suited for commercial production as inoculants. Inoculants are used in several forms such as mixed with peat as a carrier, coated on seeds or directly as a liquid inoculant. In soils where soybeans are routinely grown, the inoculant strain typically forms only a small number of the nodules on the roots of the soybean plant (e.g. Kvien *et al.*, 1981; Ellis *et al.*, 1984; Howle *et al.*, 1987). The indigenous soil strains form the bulk of the nodules. This is known as the problem of competition. The indigenous strains have unknown characteristics which give them an advantage in nodulation. Thus inoculant strains, whether natural or genetically enhanced for superior nitrogen fixation, do not substantially enhance plant productivity since they are incapable of forming the bulk of the nodules on the plant's roots. This invention addresses that limitation by having enhanced competitiveness due to mutation with transposon Tn5.

SUMMARY OF THE INVENTION

The present invention is directed to an isolated strain of Bradyrhizobium having increased nodulation characteristics, wherein a gene comprising a nucleotide sequence that hybridizes to the nucleotide sequence of SEQ ID NO:1 or SEQ ID NO:2 under 5X SSC and 42°C wash conditions is not expressed. The strain may include a gene that may at least partially comprise SEQ ID NO:1 or SEQ ID NO:2. Preferably, the gene may comprise SEQ ID NO:1 and SEQ ID NO:2, wherein SEQ ID NO:1 is located upstream of SEQ ID NO:2.

The present invention is also directed to a strain of Bradyrhizobium having a deposit number of NRRL-B-30052 or NRRL-B-30053.

In another embodiment of the present invention, the invention is directed to a method for promoting nodulation of a leguminous plant, comprising:

(i) inoculating a plant or a place near a plant root with a nodulating effective amount of an inoculum comprising an isolated strain of Bradyrhizobium having increased nodulation characteristics, wherein a gene comprising a nucleotide sequence that hybridizes to the nucleotide sequence of SEQ ID NO:1 or SEQ ID NO:2 under 5X SSC and 42°C wash conditions is not expressed, and

(ii) allowing the Bradyrhizobium strain to inoculate the root.

In this method the leguminous plant may be soybean, cowpea mungbean or siratro.

In another embodiment of the invention, the invention is also directed to an isolated gene comprising a nucleotide sequence that hybridizes to the nucleotide sequence of SEQ ID NO:1 or SEQ ID NO:2 under 5X SSC and 42°C wash conditions. The gene may comprise at least in part SEQ ID NO:1 or SEQ ID NO:2. The gene also may comprise SEQ ID NO:1 and SEQ ID NO:2, wherein SEQ ID NO:1 is located upstream of SEQ ID NO:2.

The invention is also directed to a plant seed coated with any of the Bradyrhizobium strain discussed above.

In another embodiment, the invention is directed to a composition comprising an isolated strain of Bradyrhizobium having increased nodulation characteristics, wherein a gene comprising a nucleotide sequence that hybridizes to the nucleotide sequence of SEQ ID NO:1 or SEQ ID NO:2 under 5X SSC and 42°C wash conditions is not expressed, and an agriculturally acceptable carrier thereof.

These and other objects of the invention will be more fully understood from the following description of the invention, the referenced drawings attached hereto and the claims appended hereto.

BRIEF DESCRIPTION OF THE DRAWINGS

The present invention will become more fully understood from the detailed description given hereinbelow, and the accompanying drawings which are given by way of illustration only, and thus are not limitative of the present invention, and wherein;

Fig. 1 shows nodule occupancy of I-110 ARS and BJ5019 when mixed together with varying proportions of USDA 438 and inoculated onto soybean plants.

Fig. 2 shows nodule Occupancy of BJ5019 when mixed with other *B. japonicum* strains at a ratio of 1:100 (BJ5019:other strain).

Fig. 3 shows nodule Occupancy of BJ5019 on other host plants in competition with I-110 ARS.

Fig. 4 shows the flanking regions of the Tn5 insertion site (SEQ ID NOS:1 and 2).

Table 1 shows nodulation of soybeans by mixtures of BJ5019 and TA11 Nod⁺

Table 2 shows nodulation of soybeans by mixtures of BJ5019 and *B. japonicum* strain 119

DETAILED DESCRIPTION OF THE INVENTION

As used herein, "genetic element" may be any nucleotide sequence that affects the expression of a particular gene or phenotype. A gene may be a genetic element.

A gene is a unit of nucleotide sequence that encodes a protein. In the invention, the gene is at least partly comprised of SEQ ID NO:1 or SEQ ID NO:2, or both. The gene may also comprise SEQ ID NO:1 and SEQ ID NO:2, wherein SEQ ID NO:1 is upstream of SEQ ID NO:2. Moreover, SEQ ID NO:1 and SEQ ID NO:2 may be contiguous. Preferably, this gene is derived from *Bradyrhizobium*. Preferably, the *Bradyrhizobium* is *Bradyrhizobium elkanii* or *Bradyrhizobium japonicum*. Most preferably, the gene is derived from *B. japonicum*.

It is also understood that the gene that hybridizes to SEQ ID NO:1 and/or SEQ ID NO:2 may be varied, as certain non-functional variations are possible without affecting the activity of the gene. Thus, the gene may contain sequences that preferably hybridize to the SEQ ID NO:1 or SEQ ID NO:2 or both in either contiguous or individual form, under 5X SSC and 42°C wash conditions.

In the present invention, the genetic element may be mutated. Preferably, the mutation may be made so that the gene is either not expressed, which is sometimes termed knock-out mutant, or expressed in low amounts. The mutation may be caused by chemical means such as EMS or MMS mutagenesis, or by sited directed mutagenesis such as by insertion of a disrupting genetic sequence.

Other methods include the insertion of transposons or insertion sequences. The insertion sequence may contain a sequence that codes for a selective marker, such as an antibiotic.

In the mid-western soybean growing areas of the U.S., serocluster 123 strains of *B. japonicum* (comprised of serogroups 123, 127 and 129 strains) are the dominant indigenous strains and are highly competitive. USDA 438 is a representative of serocluster 123. The nodule occupancy of BJ5019 and I-110 ARS when mixed with various proportions of USDA 438 is shown in Fig. 1. I-110 ARS is a derivative of USDA 110 which was selected for spontaneous resistance to azide, rifampin and streptomycin (USDA/ARS *Rhizobium* Germplasm Resource Collection) and is useful as a substitute for USDA 110 because it is easily distinguished due to the strain's resistance to those compounds. The number of BJ5019 cells required for 50% nodule occupancy is more than 100-fold less than with I-110 ARS; and for 25% nodule occupancy is almost 1000-fold less. Thus, in this type of experiment, BJ5019 is markedly enhanced for competitiveness relative to a derivative of the parent strain.

That BJ5019 is enhanced in competitiveness with other *B. japonicum* strains is illustrated in Fig. 2. In this figure, the results are shown from an experiment where BJ5019 was mixed at a ratio of 1:100 with a representative of other serogroup strains. It is apparent that BJ5019 is enhanced in competitiveness with all the strains tested.

Two *B. japonicum* strains, 119 (Patent No. 4,863,866), and TA11 Nod⁺ (Patent No. 5,021,076) are claimed to be enhanced in nodulation and/or nitrogen fixation. Both of these strains were derived from USDA 110. Tables 1 and 2 illustrate that BJ5019 is superior to these strains in nodulation ability at a ratio of 1:1 in the inoculum; BJ5019 formed 81% of the nodules on soybean when mixed with strain 119 (U.S. Patent No. 4,863,866 herein incorporated by reference) (Table 2) and 90% of the nodules when mixed with TA11 Nod⁺ (U.S. Patent No. 5,021,076 herein incorporated by reference)(Table 1).

Table 1. Nodulation of soybeans by mixture of *B. japonicum* strains BJ5019 and TA11 Nod⁺ (U.S. Patent No. 5,021,076)

Ratio of strains in the inoculum		Ratio of strains in the nodules		
TA11 Nod ⁺	BJ5019	TA11 Nod ⁺	BJ5019	Both
1	1	0	90	10
10	1	23	65	12
100	1	73	23	4

The antibiotic resistance markers on strain TA11 Nod⁺ are rifampicin, streptomycin, and azide. Strain BJ5019 is resistant to kanamycin and streptomycin. Nodule occupancy by BJ5019 was obtained by scoring growth on media containing kanamycin, while occupancy by TA11 Nod⁺ was determined by plating bacteroids isolated from nodules on rifampicin containing media.

Table 2. Nodulation of soybeans by mixture of *B. japonicum* strains 119 (U.S. Patent No. 4,863,866) and BJ5019

Ratio of strains in the inoculum		Ratio of strains in the nodules		
Strain 119	BJ5019	Strain 119	BJ5019	Both
1	1	nd	81	nd
10	1	nd	40	nd
100	1	nd	8	nd

nd, not determined.

The antibiotic marker on strain 119 is kanamycin resistant. Strain BJ5019 is resistant to kanamycin and streptomycin. Nodule occupancy by BJ5019 was obtained by scoring growth on media containing kanamycin. Independent analysis of nodule occupancy by strain 119 was not technically possible due to limitations of antibiotic marker selection and serotyping (both strains belong to the same serogroup, e.g., USDA 110).

B. japonicum nodulates other legume plants in addition to soybean. That the enhanced competitive nodulation phenotype is not specific to soybean is illustrated in Fig. 3. When co-inoculated onto cowpea, mungbean and siratro, BJ5019 formed more than 80% of the nodules on these legumes when mixed at a 100:1 ratio (I-110ARS: BJ5019).

The foregoing demonstrates that new mutant strains of *B. japonicum*, obtained after transposon Tn5 mutagenesis, nodulates soybeans and other host legume plants significantly better than the parent strain and many other *B. japonicum* strains, when co-inoculated with these other strains.

In addition to inoculating the soil, a composition containing the Tn5 mutagenized strain of *B. japonicum* of the invention may be used to coat seeds. Coating is accomplished by immersing seeds in a *B. japonicum*-transposon Tn5 enriched solution.

The following examples are offered by way of illustration of the present invention, and not by way of limitation.

EXAMPLES

Example 1 - Mutagenesis of USDA 110. *Bradyrhizobium japonicum* strain USDA 110 was isolated from a soybean nodule and is included in a germplasm collection, USDA-ARS National *Rhizobium* Germplasm Collection, Beltsville, MD 20705. It has been widely used in research and in commercial inocula.

B. japonicum USDA 110 was mutagenized with Transposon-5 (Tn5). Transposons are naturally occurring genetic elements carrying antibiotic resistance genes. Transposon Tn5 has

genes which carry resistance to kanamycin and streptomycin. Tn5 mutagenesis of USDA 110 was performed by triparental mating as described by Ditta (1986). Individual colonies of USDA 110 harboring Tn5 were selected on media containing kanamycin and streptomycin (at 200 µg/ml) (Bhagwat *et al.*, 1991).

Example 2 - Selection of competitive nodulation phenotype. Tn5 mutants were screened for their competitive nodulation ability on the host plant *Glycine max* (soybean) cv. Williams. Nodulation assays were performed in sterile Leonard jar assemblies (Vincent, 1970). Soybean seeds were inoculated with a mixture of *B. japonicum* strains (various Tn5 mutants and strain Mc617, in the ratio of 1:100). The strain Mc617 is a Fix⁻ mutant of USDA 110 (Bhagwat *et al.*, 1991) and forms large numbers of ineffective nodules which are unable to fix N₂. Soybean plants were maintained on N-free nutrient solution for 4 weeks in a greenhouse before harvesting for nodule occupancy analysis (Bhagwat *et al.*, 1996). Surface sterilized nodules were examined for the presence of kanamycin and streptomycin resistant bacteria to determine competitiveness of Tn5 mutant strains. The Tn5 mutant which formed the greatest number of nodules (BJ5009) was selected. This strain was deposited with the Agricultural Research Service Culture Collection (NRRL) under provisions of the Budapest treaty and assigned NRRL No. B-30052. All restrictions imposed by the depositor on the availability to the public of B-30052 will be irrevocably removed upon granting the patent.

Example 3 - Confirmation that the phenotype was due to the Tn5 insertion. The selected mutant strain BJ5009 was confirmed to carry a single copy of Tn5 and the vector sequences were absent. The genomic DNA of BJ5009 flanking the Tn5 insertion was cloned at the *EcoRI* site into a suicidal vector pSUP202. The resultant plasmid was introduced into USDA 110 by triparental mating (Ditta, 1986) and exconjugants resistant to kanamycin and streptomycin (Tn5 markers) but sensitive to tetracycline (pSUP202 marker) were selected. The selected exconjugants were screened to confirm the Tn5 insertion into an identical *EcoRI* fragment as observed in BJ5009 and one such exconjugant was designated as BJ5019. This strain was deposited with the Agricultural Research Service Culture Collection (NRRL) under provisions of the Budapest

treaty and assigned NRRL No. B-30053. All restrictions imposed by the depositor on the availability to the public of B-30053 will be irrevocably removed upon granting the patent.

The strain BJ5019 was indistinguishable in competitive nodulation phenotype BJ5099.

Example 4 - *Cloning of the full-length Bradyrhizobium gene that hybridizes to SEQ ID NO:1 or SEQ ID NO:2.* The cloning of the full-length gene for which the nucleotide sequence of SEQ ID NO:1 and SEQ ID NO:2 may be a part, is accomplished using well-known molecular cloning methods, such as disclosed in for instance, Sambrook et al., which is incorporated herein by reference especially with respect to the cloning the full-length gene by hybridization to known nucleotide sequences.

Literature cited by authors before and hereinafter is more fully described below: The following is herein incorporated by reference: /

Literature Cited

U.S. Patent Documents

4,863,866 9/1989	Zablotowicz et al.	435/172.1
5,021,076 6/1991	Kuykendall et al.	435/252.2

Other Publication

The following references are herein incorporated by reference:

Bhagwat, A.A., K.C. Gross, R.E. Tully and D.L. Keister (1996). J. Bacteriol. 178:4635-4642.

Bhagwat, A.A., R.E. Tully and D.L. Keister (1991). Appl. Environ. Microbiol. 57:3496-3501.

Ditta, G. (1986). Meth. Enzymol. 118:519-528.

Ellis, W.R., G.E. Ham and E.L. Schmidt (1984). Agron. J. 76:573-576.

Howle, P.K.W., E.R. Shipe and H.D. Skipper (1987). Agron. J. 79:595-598.

Kuykendall, L.D. and D.F. Weber (1978). Appl. Environ. Microbiol. 36:915-919

Kvien, C.S., G.E. Ham and J.W. Lambert (1981). Agron. J. 76:573-576.

Vincent, J.M. (1970). A manual for the practical study of the root nodule bacteria. IPB handbook No. 15. Blackwell Scientific Publications, Oxford, U.K.

Sambrook, J., Fritsch, E. F., and Maniatis, T. (1989). Molecular Cloning: A Laboratory Manual, Second edition (New York, Cold Spring Harbor Laboratory Press)

It will be recognized that the invention is not limited to any particular theory or explanation as to the manner in which the mutation functions, the scope of the invention being defined in the following claims wherein:

What is claimed is:

1. An isolated strain of Bradyrhizobium having increased nodulation characteristics, wherein a gene comprising a nucleotide sequence that hybridizes to the nucleotide sequence of SEQ ID NO:1 or SEQ ID NO:2 under 5X SSC and 42°C wash conditions is not expressed.
2. The strain according to claim 1, wherein said gene comprises SEQ ID NO:1 or SEQ ID NO:2.
3. The strain according to claim 2, wherein said gene comprises SEQ ID NO:1 and SEQ ID NO:2, wherein SEQ ID NO:1 is located upstream of SEQ ID NO:2.
4. The strain according to claim 1, wherein said Bradyrhizobium has a deposit number of NRRL-B-30052 or NRRL-B-30053.
5. A method for promoting nodulation of a leguminous plant, comprising:
 - (i) inoculating a plant or a place near a plant root with a nodulating effective amount of an inoculum comprising an isolated strain of Bradyrhizobium having increased nodulation characteristics, wherein a gene comprising a nucleotide sequence that hybridizes to the nucleotide sequence of SEQ ID NO:1 or SEQ ID NO:2 under 5X SSC and 42°C wash conditions is not expressed, and
 - (ii) allowing the Bradyrhizobium strain to inoculate the root.
6. The method of claim 5, wherein the leguminous plant is selected from the group consisting of soybean, cowpea mungbean and siratro.

7. The method of claim 6, wherein the leguminous plant is soybean.
8. The method according to claim 5, wherein said Bradyrhizobium strain has a deposit number of NRRL-B-30052 or NRRL-B-30053.
9. An isolated gene comprising a nucleotide sequence that hybridizes to the nucleotide sequence of SEQ ID NO:1 or SEQ ID NO:2 under 5X SSC and 42°C wash conditions.
10. The gene according to claim 9, wherein said gene comprises SEQ ID NO:1 or SEQ ID NO:2.
11. The gene according to claim 10, wherein said gene comprises SEQ ID NO:1 and SEQ ID NO:2, wherein SEQ ID NO:1 is located upstream of SEQ ID NO:2.
12. A plant seed coated with the Bradyrhizobium strain according to claim 1.
13. The plant seed according to claim 12, wherein said plant is soybean.
14. A composition comprising an isolated strain of Bradyrhizobium having increased nodulation characteristics, wherein a gene comprising a nucleotide sequence that hybridizes to the nucleotide sequence of SEQ ID NO:1 or SEQ ID NO:2 under 5X SSC and 42°C wash conditions is not expressed, and an agriculturally acceptable carrier thereof.

15. The composition according to claim 14, wherein said Bradyrhizobium has a deposit number of NRRL-B-30052 or NRRL-B-30053.

11/11/2009 10:00 AM

Abstract of the Disclosure

Mutant strains of *Bradyrhizobium japonicum*, BJ5009 and BJ5019, were created by transposon mutagenesis of known *B. japonicum* strain USDA 110. The strains are characterized by superior competitiveness for nodulation of legumes in the presence of the parent strain and other *B. japonicum* strains.

2025 RELEASE UNDER E.O. 14176

FIG. 1




FIG. 2




FIG. 3




FIGURE 4

CCATCGTACGAAACCTCACTCCACNCGGTACCAGCGCACCAGCCGCGGCGCGGC
CCAGTCGGCACGACGGATTTCGATCAGCCAACGTCCGGGCGAGGTCGCCGCGAAC
GCGATGCGCTGGGTCTGGCCGGAATCGATCGCGAGCGTGTCGAGCCAATAGGGC
TTCCAGCCGTCGTCGAGCTTGTCG (SEQ ID NO:1)

(Tn5 insertion element 5)

AGCTTGTCGAGCAGGCGGAAGGGATGGCCGTGCAGGTGGAACACGGCGGTGAGG
GGCGCGGGGTTCTTGAGGGTCAGCACGACGGTGCGGCCGGTCCTGGTGCGGAAG
GCCGGCGCCGACGAGGTGGAGAAATCCGCAGGCCGCGTCCAACCGGTATCGGGT
GCACCGAGCGCGACATCGAACCAGGCGGCCTTTGAGATCGAGCTGGTCGGGC
AGGGCATTTCGAGGGAGCGGTTGTGGCGGCAACAGCGGCGCGCGCCGCTCCAGT
CTGCCGAGATCGAGAGGTTTCCGATCGGGCGGGCCTCCTTGCCGTCATGCAGC
AGAAATTGGGCCGATGTGGCTGCGTCCACAAAGGCGTCGGCCCCGTC
(SEQ ID NO:2)

09/889883

**COMBINED DECLARATION AND POWER OF ATTORNEY
FOR UNITED STATES PATENT**

As a below named inventor, I hereby declare that:

My residence address, post office address and citizenship are as stated below next to my name.

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter that which is claimed and for which a patent is sought on the invention entitled **IMPROVED INOCULANT STRAINS OF BRADYRHIZOBIUM JAPONICUM**, the specification of which is attached hereto unless the following is checked:

- ☒ The specification was filed on November 24, 2000, as United States Application No. or PCT International Patent Application No. PCT/US00/32316 and was amended on N/A (if applicable).

I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment referred to above.

I hereby acknowledge the duty to disclose information that is material to the examination of this application in accordance with Title 37, Code of Federal Regulations, § 1.56(a).

Under Title 35, United States Code, § 119(a)-(d) or § 365(b), I hereby claim foreign priority benefits of any foreign application(s) for patent or inventor's certificate or under Title 35, United States Code, § 365(a) of any PCT International application which designated at least one country other than the United States, which are listed below, and have also identified below any foreign application for patent or inventor's certificate, or of any International applications having a filing date before that of the application on which priority is claimed:

Prior Foreign Applications(s):

<u>Number</u>	<u>Country</u>	<u>Day/Month/Year filed</u>	<u>Priority Claimed</u>
PCT/US00/32316	U.S.	November 24, 2000	<input checked="" type="checkbox"/>

Under Title 35, United States Code, § 119(e), I hereby claim the benefit of priority of any United States provisional patent applications listed below:

Prior Provisional Application(s):

<u>Application Number</u>	<u>Filing Date</u>
60/167,300	November 24, 1999

Under Title 35, United States Code, § 120, I hereby claim the benefit of priority of any United States patent application(s) or under Title 35, United States Code, § 365(c) of any PCT International application designating the United States, which are listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States or PCT International applications(s) in the manner provided by the first paragraph of Title 35, United States Code, § 112, and I acknowledge the duty to disclose information that is material to patentability as defined in Title 37, Code of Federal Regulations, § 1.56 that became available between the filing date of the prior application and the

national or PCT international filing date of this application:

Prior U.S. Application(s):

<u>Serial No.</u>	<u>Filing Date</u>	<u>Status: Patented, Pending, Abandoned</u>
-------------------	--------------------	---

I hereby appoint as my attorneys, with full power of substitution and revocation, to prosecute the patent application identified above, and to transact all business connected therewith, in the U.S. Patent and Trademark Office and all other competent International/Foreign authorities: Stephen A. Becker, Reg. No. 26,527; John G. Bisbikis, Reg. No. 37,095; Daniel Bucca, Reg. No. 42,368; Kenneth L. Cage, Reg. No. 26,151; Jennifer Chen, Reg. No. 42,404; Bernard P. Codd, Reg. No. 46,429; Lawrence T. Cullen, Reg. No. 44,489; Paul Devinsky, Reg. No. 28,553; Margaret M. Duncan, Reg. No. 30,879; Shamita De. Etienne-Cummings, Reg. No. 46,072; Ramyar M. Farid, Reg. No. 46,692; Brian E. Ferguson, Reg. No. 36,801; Michael E. Fogarty, Reg. No. 36,139; John R. Fuisz, Reg. No. 37,327; Willem F. Gadiano, Reg. No. 37,136; Keith E. George, Reg. No. 34,111; Matthew V. Grumbling, Reg. No. 44,427; John A. Hankins, Reg. No. 32,029; Eric J. Kraus, Reg. No. 36,190; Catherine Krupka, Reg. No. 46,227; Jack Q. Lever, Reg. No. 28,149; Raphael V. Lupo, Reg. No. 28,363; Burman Y. Mathis III, Reg. No. 44,907; Michael A. Messina, Reg. No. 33,424; Dawn L. Palmer, Reg. No. 41,238; Joseph H. Paquin, Jr., Reg. No. 31,647; Scott D. Paul, Reg. No. 42,984; William D. Pegg, Reg. No. 42,988; Robert L. Price, Reg. No. 22,685; Gene Z. Robinson, Reg. No. 33,351; Mahshid D. Saadat, Reg. No. 48,218; Joy Ann G. Serauskas, Reg. No. 27,952; David A. Spenard, Reg. No. 37,449; Arthur J. Steiner, Reg. No. 26,106; David L. Stewart, Reg. No. 37,578; Wesley Strickland, Reg. No. 44,363; Michael D. Switzer, Reg. No. 39,552; David M. Tennant, Reg. No. 48,362; Daniel S. Trainor, Reg. No. 43,959; Kelli N. Watson, Reg. No. 47,170; Cameron K. Weiffenbach, Reg. No. 44,488; Aaron Weisstuch, Reg. No. 41,557; Edward J. Wise, Reg. No. 34,523; Jeffrey A. Woller, Reg. No. 48,041; Alexander V. Yampolsky, Reg. No. 36,324; and Robert W. Zelnick, Reg. No. 36,976, all of McDermott, Will & Emery.

I hereby authorize the U.S. attorneys named herein to accept and follow instructions from University of Maryland, its legal representatives, successors or assigns, as to any action to be taken in the Patent and Trademark Office regarding this application, and in all other competent International/Foreign authorities regarding the above-identified invention, without direct communication with me.

PLEASE DIRECT ALL CORRESPONDENCE AND TELEPHONE CALLS TO:

WILLEM F. GADIANO, ESQ.
MCDERMOTT, WILL & EMERY
600 13th Street, N.W.
Washington, D.C. 20005
Telephone No.: (202) 756-8373

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Full name of First/Sole Inventor: Arvind A. Bhagwat
Residence Address: 12106 Lemar Court, Silver Spring, Maryland 20904
Post Office Address: Same as Residence Address
Citizenship: United States

Inventor's signature: _____

Date: _____

2-00
Full name of Second Inventor: Donald L. Keister
Residence Address: 12408 Silverbitch Lane, Laurel, Maryland 20708
Post Office Address: Same as Residence Address
Citizenship: United States

Inventor's signature: Donald L. Keister

Date: 11/16/01

**COMBINED DECLARATION AND POWER OF ATTORNEY
FOR UNITED STATES PATENT**

As a below named inventor, I hereby declare that:

My residence address, post office address and citizenship are as stated below next to my name.

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter that which is claimed and for which a patent is sought on the invention entitled **IMPROVED INOCULANT STRAINS OF BRADYRHIZOBIUM JAPONICUM**, the specification of which is attached hereto unless the following is checked:

- ☒ The specification was filed on November 24, 2000, as United States Application No. or PCT International Patent Application No. PCT/US00/32316 and was amended on N/A (if applicable).

I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment referred to above.

I hereby acknowledge the duty to disclose information that is material to the examination of this application in accordance with Title 37, Code of Federal Regulations, § 1.56(a).

Under Title 35, United States Code, § 119(a)-(d) or § 365(b), I hereby claim foreign priority benefits of any foreign application(s) for patent or inventor's certificate or under Title 35, United States Code, § 365(a) of any PCT International application which designated at least one country other than the United States, which are listed below, and have also identified below any foreign application for patent or inventor's certificate, or of any International applications having a filing date before that of the application on which priority is claimed:

Prior Foreign Applications(s):

<u>Number</u>	<u>Country</u>	<u>Day/Month/Year filed</u>	<u>Priority Claimed</u>
PCT/US00/32316	U.S.	November 24, 2000	<input checked="" type="checkbox"/>

Under Title 35, United States Code, § 119(e), I hereby claim the benefit of priority of any United States provisional patent applications listed below:

Prior Provisional Application(s):

<u>Application Number</u>	<u>Filing Date</u>
60/167,300	November 24, 1999

Under Title 35, United States Code, § 120, I hereby claim the benefit of priority of any United States patent application(s) or under Title 35, United States Code, § 365(c) of any PCT International application designating the United States, which are listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States or PCT International applications(s) in the manner provided by the first paragraph of Title 35, United States Code, § 112, and I acknowledge the duty to disclose information that is material to patentability as defined in Title 37, Code of Federal Regulations, § 1.56 that became available between the filing date of the prior application and

the national or PCT international filing date of this application:

Prior U.S. Application(s):**Serial No.****Filing Date****Status: Patented, Pending, Abandoned**

I hereby appoint as my attorneys, with full power of substitution and revocation, to prosecute the patent application identified above, and to transact all business connected therewith, in the U.S. Patent and Trademark Office and all other competent International/Foreign authorities: Stephen A. Becker, Reg. No. 26,527; John G. Bisbikis, Reg. No. 37,095; Daniel Bucca, Reg. No. 42,368; Kenneth L. Cage, Reg. No. 26,151; Jennifer Chen, Reg. No. 42,404; Bernard P. Codd, Reg. No. 46,429; Lawrence T. Cullen, Reg. No. 44,489; Paul Devinsky, Reg. No. 28,553; Margaret M. Duncan, Reg. No. 30,879; Shamita De. Etienne-Cummings, Reg. No. 46,072; Ramyar M. Farid, Reg. No. 46,692; Brian E. Ferguson, Reg. No. 36,801; Michael E. Fogarty, Reg. No. 36,139; John R. Fuisz, Reg. No. 37,327; Willem F. Gadiano, Reg. No. 37,136; Keith E. George, Reg. No. 34,111; Matthew V. Grumbling, Reg. No. 44,417; John A. Hankins, Reg. No. 32,029; Eric J. Kraus, Reg. No. 36,190; Catherine Krupka, Reg. No. 46,227; Jack Q. Lever, Reg. No. 28,149; Raphael V. Lupo, Reg. No. 28,363; Burman Y. Mathis III, Reg. No. 44,907; Michael A. Messina, Reg. No. 33,424; Dawn L. Palmer, Reg. No. 41,238; Joseph H. Paquin, Jr., Reg. No. 31,647; Scott D. Paul, Reg. No. 42,984; William D. Pegg, Reg. No. 42,988; Robert L. Price, Reg. No. 22,685; Gene Z. Rubinson, Reg. No. 33,351; Mahshid D. Saadat, Reg. No. 48,218; Joy Ann G. Serauskas, Reg. No. 27,952; David A. Spenard, Reg. No. 37,449; Arthur J. Steiner, Reg. No. 26,106; David L. Stewart, Reg. No. 37,578; Wesley Strickland, Reg. No. 44,363; Michael D. Switzer, Reg. No. 39,552; David M. Tennant, Reg. No. 48,362; Daniel S. Trainor, Reg. No. 43,959; Kelli N. Watson, Reg. No. 47,170; Cameron K. Weiffenbach, Reg. No. 44,488; Aaron Weisstuch, Reg. No. 41,557; Edward J. Wise, Reg. No. 34,523; Jeffrey A. Woller, Reg. No. 48,041; Alexander V. Yampolsky, Reg. No. 36,324; and Robert W. Zelnick, Reg. No. 36,976, all of McDermott, Will & Emery.

I hereby authorize the U.S. attorneys named herein to accept and follow instructions from University of Maryland, its legal representatives, successors or assigns, as to any action to be taken in the Patent and Trademark Office regarding this application, and in all other competent International/Foreign authorities regarding the above-identified invention, without direct communication with me.

PLEASE DIRECT ALL CORRESPONDENCE AND TELEPHONE CALLS TO:

WILLEM F. GADIANO, ESQ.
MCDERMOTT, WILL & EMERY
600 13th Street, N.W.
Washington, D.C. 20005
Telephone No.: (202) 756-8373

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

1-00
Full name of First/Sole Inventor: Arvind A. Bhagwat
Residence Address: 12106 Lemar Court, Silver Spring, Maryland 20904
Post Office Address: Same as Residence Address
Citizenship: United States

Inventor's signature: _____

Date: 11-16-01

Full name of Second Inventor: Donald L. Keister
Residence Address: 12408 Silverbitch Lane, Laurel, Maryland 20708
Post Office Address: Same as Residence Address
Citizenship: United States

Inventor's signature: _____

Date: _____

SEQUENCE LISTING

<110> Bhagwat, Arvind
 Keister, Donald
 <120> Improved Inoculant Strains of Bradyrhizobium Japonicum
 <130> Attorney Docket 55859-019
 <140> 09/889,883

<160> 2

<170> PatentIn version 3.0
 <210> 1
 <211> 186
 <212> DNA
 <213> Bradyrhizobium japonicum
 <220>
 <221> misc_feature
 <222> ()..()
 <223> "n" means A, T, C, or G
 <400> 1

ccatcgtacg aaacctcaact ccacngcgta ccagcgcacc agccgcggcg cggcccagtc 60
 ggcacgacgg attcgatcag ccaacgtccg ggcgaggctg ccgcgaacgc gatgcgctgg 120
 gtctggccgg actcgatcgc gacggtgtcg agccaatagg gcttcagcc gtcgtcgagc 180
 ttgtcg 186

<210> 2
 <211> 370
 <212> DNA
 <213> Bradyrhizobium japonicum

<400> 2
 agcttgtega gcaggcggaa gggatggccg tgcaggtgga acacggcggt gaggggcgcg 60
 gggttcttga gggtcagcac gacggtgcgg ccggtcctgg tgcggaaggc cggcgccgac 120
 gaggtggaga aatccgcagg ccgcgtccaa ccggtatcgg gtgcaccgag cgcgacatcg 180
 aaccgcaggg cgcctttgag atcgagctgg tcgggcaggg cattcgcagg gagcggttgt 240
 ggcggcaaca gcggcgcgcg ccgctccagt ctgccggaga tcgagagggt tccgatcggg 300
 cgggcctcct tgccgtcatg cagcagaaat tgggccgatg tggctgcgtc cacaaggcg 360
 tcggcccgtc 370

CONTINUED, # 12